کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3393518 1221347 2007 22 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Preventing rabies with the Verorab® vaccine: 1985–2005: Twenty years of clinical experience
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Preventing rabies with the Verorab® vaccine: 1985–2005: Twenty years of clinical experience
چکیده انگلیسی

SummaryPurified rabies vaccine cultured on Vero cells (Verorab®, sanofi pasteur) is WHO-approved for pre- and post-exposure prophylaxis by intradermal and intramuscular routes. During 20 years of use, over 40 million doses of Verorab® have been administered in more than 100 countries. No serious adverse event due to Verorab® has been reported in clinical trials involving 3937 persons, and Verorab® is better tolerated than human diploid cell vaccine (HDCV).Pre-exposure prophylaxis is confirmed immunogenic in 1437 subjects by all routes, with prompt responses following boosting; Verorab® boosts effectively subjects pre-immunized with HDCV. Unlike HDCV, Verorab® is not associated with post-boosting serum sickness. In the absence of data in immunodeficient/HIV-positive individuals, pre-exposure immunization is urged as early as possible.Essen, Zagreb, Thai Red Cross Intradermal (TRC-ID) and other post-exposure intramuscular and intradermal regimens are documented. Two thousand one hundred and eighty-three subjects received post-exposure prophylaxis, including 874 high risk, severe or confirmed rabid attacks. Co-administration of rabies immune globulin (RIG) does not affect neutralizing antibody levels when Essen or TRC-ID regimens are employed; levels are lower with the Zagreb regimen.Verorab® has been administered safely and effectively post-exposure to 251 pregnant women, without any increase in congenital malformations or spontaneous abortions. From a pediatric perspective, safety and efficacy have been demonstrated in 759 children (0–15 years).Intradermal post-exposure Verorab® is an effective and inexpensive option for developing countries. Inadvertent subcutaneous administration does not reduce immunogenicity. WHO already strongly recommends the replacement of nerve tissue vaccines with modern vaccines. Extensive clinical experience supports the use of Verorab® for intramuscular and intradermal pre- and post-exposure prophylaxis, including in special situations.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Travel Medicine and Infectious Disease - Volume 5, Issue 6, November 2007, Pages 327–348
نویسندگان
,